Please take a moment to review the important CE information on this page.

To earn free CE credit for watching this program, you must complete the online CE test and evaluation. You must be registered and signed-in in order to take the test online. Upon successful completion of the test and the evaluation, you will be asked to select your professional category and will be able to print the appropriate credit certificate right from your computer. You must answer a minimum of 8 out of 10 questions correctly in order to earn CE credit.

Take the online CE test and evaluation.

If you would like to download a list of the questions to have with you when you watch the show, click download the CE questions.

Click here for a list of CME Requirements by State.

Adjuvant Therapy in Breast Cancer: From Testing to Treatment
This program is available for credit until February 24, 2009

Accreditation

Physicians

The National Comprehensive Cancer Network (NCCN) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education to physicians.

NCCN designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Nurses

This activity is approved for 1.0 contact hour. National Comprehensive Cancer Network is an approved provider of continuing nursing education by PA State Nurses Association, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation.

Approval as a provider refers to recognition of educational activities only and does not imply ANCC Commission on Accreditation or PA Nurses approval or endorsement of any product.

Kristina M. Gregory, RN, MSN, OCN, is our nurse planner for this educational activity.

Contact NCCN at webcasts@nccn.org.

Program Overview
In response to the burgeoning data regarding patient risk assessment and the selection of adjuvant hormonal, biologic, and cytotoxic therapies, the National Comprehensive Cancer Network (NCCN), in conjunction with Discovery Health, has brought together members of the NCCN Breast Cancer Guidelines Panel to discuss the use of adjuvant therapy in the management of breast cancer. The program will focus on issues such as indications for systemic adjuvant therapy, predictive and prognostic factors in adjuvant treatment, endocrine therapy for women, targeted therapy for HER2-positive tumors, and the appropriate use of cytotoxic chemotherapy.

Learning Objectives
At the conclusion of this program, participants should be able to:

• Describe various testing options for hormonal and HER2 status
• Explain the limitations and strengths of existing risk assessment tools
• Identify the role of tamoxifen therapy in hormone receptor-positive younger women
• Describe the role of aromatase inhibitors and the data supporting their use in hormone receptor-positive postmenopausal women
• Discuss the use of cytotoxic chemotherapy based on risk assessment
• Summarize the role of trastuzumab in treatment of HER2-positive tumors in the adjuvant setting

Target Audience
This educational activity is designed to meet the needs of physicians, nurses, and other clinical professionals who manage patients with cancer.

Faculty Disclosure Information
All faculty participating in NCCN continuing education activities are expected to disclose any conflict(s) of interest related to the content of their presentation(s) as defined by the ACCME's and ANCC's Standards for Commercial Support.

The speaker(s) listed below have disclosed that they have financial interests, arrangements, or affiliations with the manufacturer of any products or devices to be discussed in this activity or who may financially support the activity:

Robert W. Carlson, MD
Consultant: AstraZeneca, Genomic Health, Pfizer
Researcher: AstraZeneca, Genentech

Lori J. Goldstein, MD
Research Support: AstraZeneca, Bristol-Myers Squibb, Genomic Health, GlaxoSmithKline, Johnson & Johnson, Merck, sanofi-aventis, Wyeth
Consultant/Advisory Board Member: AKA Pharmaceuticals, Amgen, AstraZeneca, Bayer HealthCare (formerly Berlex), Bristol-Myers Squibb, Eli Lilly, Eisai, Genentech, Genomic Health, GlaxoSmithKline, Novartis, Pfizer, Pharmion, Roche, sanofi-aventis
Speaker: Bristol-Myers Squibb, Novartis, Pfizer, sanofi-aventis

Clifford A. Hudis, MD
Speaker: AstraZeneca, Amgen, Bristol-Myers Squibb, Genentech, GlaxoSmithKline, Novartis, Pfizer, Roche, sanofi-aventis
Stockholder: Genomic Health
Research Support: Breast Cancer Research Foundation, Kosan Biosciences, National Cancer Institute

All speakers have indicated that their presentations will include discussion of investigational or unlabeled uses of commercial products.

Commercial Support
Supported by educational grants from Bristol-Myers Squibb Company, Genentech BioOncology, Novartis Oncology, and Pfizer Inc.